H. Lundbeck, launch of Azilect® commenced in Europe

H. Lundbeck A/S and Teva Pharmaceutical Industries Ltd. (Teva) announced today that Azilect®, a once-daily treatment for Parkinson’s disease (PD) both as monotherapy in patients with early PD and as an adjunct treatment in moderate to advanced disease, is now available in the United Kingdom.